FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008325699> ?p ?o ?g. }

• W2008325699 endingPage "e0103258" @default.
• W2008325699 startingPage "e0103258" @default.
• W2008325699 abstract "The epidermal growth factor (EGF) is responsible for the activation of intracellular signal transducers that act on cell-cycle progression, cell motility, angiogenesis and inhibition of apoptosis. However, cells can block these effects activating opposite signaling pathways, such as the transforming growth factor beta 1 (TGFβ1) pathway. Thus changes in expression levels of EGF and TGFB1 in renal cells might modulate the renal cell carcinoma (RCC) development, in consequence of changes in regulatory elements of signaling networks such as the microRNAs (miRNAs). Our purpose was to investigate the synergic role of EGF+61G>A and TGFB1+869T>C polymorphisms in RCC development. Genetic polymorphisms were studied by allelic discrimination using real-time PCR in 133 RCC patients vs. 443 healthy individuals. The circulating EGF/EGFR-MAPK-related miR-7, miR-221 and miR-222 expression was analyzed by a quantitative real-time PCR in plasma from 22 RCC patients vs. 27 healthy individuals. The intermediate/high genetic proliferation profile patients carriers present a significantly reduced time-to-progression and a higher risk of an early relapse compared with the low genetic proliferation profile carriers (HR = 8.8, P = 0.038) with impact in a lower overall survival (Log rank test, P = 0.047). The RCC patients presented higher circulating expression levels of miR-7 than healthy individuals (6.1-fold increase, P<0.001). Moreover, the intermediate/high genetic proliferation profile carriers present an increase in expression levels of miR-7, miR-221 and miR-222 during the RCC development and this increase is not observed in low genetic proliferation profile (P<0.001, P = 0.004, P<0.001, respectively). The stimulus to angiogenesis, cell-cycle progression and tumoral cells invasion, through activation of EGFR/MAPK signaling pathway in intermediate/high proliferation profile carriers is associated with an early disease progression, resulting in a poor overall survival. We also demonstrated that the intermediate/high proliferation profile is an unfavorable prognostic factor of RCC and miR-7, miR-221 and miR-222 expressions may be useful phenotype biomarkers of EGFR/MAPK activation." @default.
• W2008325699 created "2016-06-24" @default.
• W2008325699 creator A5001085477 @default.
• W2008325699 creator A5002735203 @default.
• W2008325699 creator A5011244825 @default.
• W2008325699 creator A5015968029 @default.
• W2008325699 creator A5017330209 @default.
• W2008325699 creator A5018172201 @default.
• W2008325699 creator A5045380609 @default.
• W2008325699 creator A5049034018 @default.
• W2008325699 creator A5077355971 @default.
• W2008325699 date "2015-04-24" @default.
• W2008325699 modified "2023-10-15" @default.
• W2008325699 title "Combined Influence of EGF+61G>A and TGFB+869T>C Functional Polymorphisms in Renal Cell Carcinoma Progression and Overall Survival: The Link to Plasma Circulating MiR-7 and MiR-221/222 Expression" @default.
• W2008325699 cites W1480344559 @default.
• W2008325699 cites W1966789823 @default.
• W2008325699 cites W1968340154 @default.
• W2008325699 cites W1976500266 @default.
• W2008325699 cites W1979483594 @default.
• W2008325699 cites W1992091927 @default.
• W2008325699 cites W1995235833 @default.
• W2008325699 cites W2004804925 @default.
• W2008325699 cites W2019607817 @default.
• W2008325699 cites W2023642368 @default.
• W2008325699 cites W2025222882 @default.
• W2008325699 cites W2027864728 @default.
• W2008325699 cites W2033090511 @default.
• W2008325699 cites W2047057592 @default.
• W2008325699 cites W2048422848 @default.
• W2008325699 cites W2052242868 @default.
• W2008325699 cites W2053872218 @default.
• W2008325699 cites W2055635603 @default.
• W2008325699 cites W2070186254 @default.
• W2008325699 cites W2078020286 @default.
• W2008325699 cites W2080126052 @default.
• W2008325699 cites W2083019028 @default.
• W2008325699 cites W2084400739 @default.
• W2008325699 cites W2091962867 @default.
• W2008325699 cites W2096339171 @default.
• W2008325699 cites W2102913835 @default.
• W2008325699 cites W2105478580 @default.
• W2008325699 cites W2110320497 @default.
• W2008325699 cites W2114570899 @default.
• W2008325699 cites W2116406455 @default.
• W2008325699 cites W2125545284 @default.
• W2008325699 cites W2125742574 @default.
• W2008325699 cites W2129407204 @default.
• W2008325699 cites W2132939465 @default.
• W2008325699 cites W2134737949 @default.
• W2008325699 cites W2139408538 @default.
• W2008325699 cites W2142247849 @default.
• W2008325699 cites W2142274244 @default.
• W2008325699 cites W2142957616 @default.
• W2008325699 cites W2146865265 @default.
• W2008325699 cites W2152922289 @default.
• W2008325699 cites W2153281193 @default.
• W2008325699 cites W2162128852 @default.
• W2008325699 cites W2165011061 @default.
• W2008325699 cites W2170428165 @default.
• W2008325699 cites W2316296578 @default.
• W2008325699 cites W2335012284 @default.
• W2008325699 cites W2807075234 @default.
• W2008325699 doi "https://doi.org/10.1371/journal.pone.0103258" @default.
• W2008325699 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4409046" @default.
• W2008325699 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25909813" @default.
• W2008325699 hasPublicationYear "2015" @default.
• W2008325699 type Work @default.
• W2008325699 sameAs 2008325699 @default.
• W2008325699 citedByCount "19" @default.
• W2008325699 countsByYear W20083256992015 @default.
• W2008325699 countsByYear W20083256992016 @default.
• W2008325699 countsByYear W20083256992017 @default.
• W2008325699 countsByYear W20083256992019 @default.
• W2008325699 countsByYear W20083256992020 @default.
• W2008325699 countsByYear W20083256992021 @default.
• W2008325699 countsByYear W20083256992022 @default.
• W2008325699 countsByYear W20083256992023 @default.
• W2008325699 crossrefType "journal-article" @default.
• W2008325699 hasAuthorship W2008325699A5001085477 @default.
• W2008325699 hasAuthorship W2008325699A5002735203 @default.
• W2008325699 hasAuthorship W2008325699A5011244825 @default.
• W2008325699 hasAuthorship W2008325699A5015968029 @default.
• W2008325699 hasAuthorship W2008325699A5017330209 @default.
• W2008325699 hasAuthorship W2008325699A5018172201 @default.
• W2008325699 hasAuthorship W2008325699A5045380609 @default.
• W2008325699 hasAuthorship W2008325699A5049034018 @default.
• W2008325699 hasAuthorship W2008325699A5077355971 @default.
• W2008325699 hasBestOaLocation W20083256991 @default.
• W2008325699 hasConcept C104317684 @default.
• W2008325699 hasConcept C118131993 @default.
• W2008325699 hasConcept C121608353 @default.
• W2008325699 hasConcept C126322002 @default.
• W2008325699 hasConcept C134018914 @default.
• W2008325699 hasConcept C145059251 @default.
• W2008325699 hasConcept C170493617 @default.
• W2008325699 hasConcept C2776362946 @default.
• W2008325699 hasConcept C2777472916 @default.
• W2008325699 hasConcept C2779256057 @default.

• next